Cervarix Articles
Merck & Co's Gardasil and GSK's Cervarix to be available to developing countries via UNICEF tender
9 May 2013
Adult vaccines market controlled by GSK and Merck
15 April 2013
US consumer groups call on FTC to investigate anti-competitive practices of vaccine makers
21 March 2012
GlaxoSmithKline gets amended license for Cervarix; initiates Ph III study of shingles vaccine
26 August 2010
New Ph III data shows Merck & Co's Gardasil was effective against anal disease caused by HPV 6,11,16, and 18
18 February 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise; applause from Science Minister
5 February 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Merck & Co aims to expand Gardasil usage to boost flagging sales
18 January 2010
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
GSK in 1.5 billion-euro deal with Brazil for pneumococcal vaccine; first Cervarix death reported
29 September 2009
US FDA reviews supports GlaxoSmithKline’s Cervarix and Merck & Co’s Gardasil in males
7 September 2009
GSK submits final data to FDA from Cervarix BLA
2 April 2009
Wales' HPV vacc catch up campaign accelerated
30 March 2009
Spain withdraws batch of Gardasil after two adverse events
16 February 2009
AstraZeneca's Nobel link not a conflict of interest
12 January 2009
Cervarix could achieve 20-year response; study
24 November 2008
UPDATE: "Wrong" HPV vacc selected in UK
3 November 2008
"Wrong" HPV vacc selected in UK
3 November 2008
Antigenics submits MAA for Oncophage
3 November 2008
US media accused over vacc fears by blogger
3 November 2008
US and UK Prix Galien awards 2008, winners announced
6 October 2008
Two new indications for Merck & Co's HPV vacc
22 September 2008
Wales begins HPV vaccination program
8 September 2008
UK to expand HPV vaccine program
28 July 2008
"Unfounded" claims, but GSK exec quits Ofsted
21 July 2008
Further delays for GSK's Cervarix vaccine
7 July 2008
6.4 years protection with GSK's Cervarix
26 May 2008
GSK in cliffhanger on vacc reimbursement
5 May 2008
Pertussis vacc for all adults in France
28 April 2008
Belgium's drugmakers welcome 26 new drugs
31 March 2008
Merck & Co's Gardasil gets priority US review
31 March 2008
South Africa approves HPV vaccines
24 March 2008
GSK HPV vacc provides longest protection
17 March 2008
Danish gov approves free HPV vaccination
10 March 2008
HPV vacc and screening "both required"
11 February 2008
France adopts Gardasil as human papillomavirus vaccine
21 January 2008
Stock Commentary - Europe - week to January 7, 2008
7 January 2008
Cervarix induced ABs present in cervix two years post-treatment
12 November 2007
UK govt announces HPV vaccine timetable
5 November 2007
UPDATE: HPV vaccine timetable revealed by UK govt
5 November 2007
Generic HPV vacc could cost under $15 per dose
22 October 2007
GSK HPV data supports prophylactic strategy
15 October 2007
EMEA clears GSK's Cervarix vaccine
1 October 2007
UK's ABPI "admonishes" Bayer, GSK and Roche
16 July 2007
GSK's Cervarix 100% effective in Ph III study
9 July 2007
FDA opts for standard review of Cervarix
11 June 2007
Stock Commentary - Europe - week to June 4, 2007
11 June 2007
GSK's Cervarix cleared in Australia
28 May 2007
Cervarix protects against HPV for over 5 years
23 April 2007
Germany introduces HPV vacc, Italy to follow
9 April 2007
GSK submits Cervarix BLA to US FDA
9 April 2007
GSK's initiates trial of Cervarix vs Merck's Gardasil
22 January 2007
GSK's Cervarix could cut cervical cancer 80%
6 November 2006
Sanofi Pasteur MSD's Gardasil beating GSK's Cervarix in race to dominate HPV vacc market
30 October 2006
Cervarix could cut UK cerv cancer deaths 76%
11 September 2006
GSK's AS04 more potent vs Aluminium adjuvant
24 July 2006
US FDA approves Merck & Co's Gardasil: First cervical cancer vacc, potential blockbuster
19 June 2006
GSK's sees strong efficacy across wide age group
12 June 2006
Gardasil gets FDA nod for cervical cancer
29 May 2006
FDA accepts GSK's Coreg CR NDA for review
20 March 2006
GSK boosts vaccs ops with $300M Corixa buy
9 May 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
Stock Commentary - Europe
8 November 2004
Showing 1-99 of 99 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
